Health News

Taxol Boosts Odds of Chronic Pain [2009-12-29]

MONDAY, Nov. 30 (HealthDay News) -- The chemotherapy drug paclitaxel (Taxol) increases the risk of chronic neuropathic pain in breast cancer survivors, a new study shows.

It included 240 women who took part in clinical trials of Taxol between 1994 and 2001. Those who experienced chemotherapy-induced peripheral neuropathy during their treatment with Taxol were three times more likely to eventually be diagnosed with chronic neuropathic pain.

The study is published in the November issue of the Journal of Pain.

The findings indicate that patients treated with Taxol should be regularly monitored for neuropathic pain after their chemotherapy ends, said the researchers from the University of Texas M.D. Anderson Cancer Center.

In certain cases, patients and doctors should review the risks and benefits for continuing treatment with Taxol if a patient is likely to experience worsening neuropathy, the study authors added.

They noted that the same cellular mechanism that's altered by Taxol to kill tumors can be toxic to normal tissue.

LATEST NEWS
Abnormal genes in DNA repair may help predict pancreatic cancer risk
Alcohol Raises Risk of Breast Cancer Recurrence
Bone-Building Drugs May Cut Breast Cancer Risk
Breast Cancer - A 'Battle' Not Only For The Women
Breast Cancer Drug Fights Lung Cancer, Too

LATEST ARTICLES
Virus Invaders
The Trouble with Celebrity Science
The Internal Flame
Targeting the Triple Threat
Super Foods for Men and Women
Men need to check for breast cancer, too
Meat on the Menu?
Long-Term Smoking Increases Colorectal Cancer Risk, Study Shows
Life Preserver?
Know Your Breasts

  • User(s) Online: 6
  • Total Visitors: 233293